Aims: Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia. This drug-drug interaction study assessed the pharmacokinetics (PK) of quizartinib when coadministered with strong or moderate cytochrome P450 3A (CYP3A) inhibitors.
CYP3A inhibitor. This dose reduction was implemented in phase 3 evaluation of quizartinib.
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| INTRODUCTION
Acute myeloid leukaemia (AML) is a heterogeneous disease characterised by clonal evolution with poor prognosis and limited treatment options for patients. [1] [2] [3] The most common driver mutations in AML include mutations in FMS-like tyrosine kinase 3 (FLT3; primarily internal tandem duplication [ITD] ), and are reported in~25% of patients with newly diagnosed disease. 4 Patients with FLT3-ITD mutated AML have a particularly poor prognosis (i.e. increased risk of relapse and shorter overall survival) following standard-of-care chemotherapy, 3, 4 making FLT3 an attractive therapeutic target.
Quizartinib is an orally administered, highly potent and selective next-generation FLT3 inhibitor in phase 3 development in patients with FLT3-ITD mutated AML (QuANTUM-R: NCT02039726;
QuANTUM-First: NCT02668653). In phase 2 studies, quizartinib treatment resulted in a composite complete remission of disease in patients with relapsed or refractory FLT3-ITD mutated AML (composite complete remission rates of 44% to 47%) and successfully bridged 34% to 42% to potentially curative hematopoietic stem cell transplantation. 5, 6 Quizartinib is generally well tolerated and is known to be associated with QT interval prolongation (corrected according to Fridericia's formula; QTcF), 7, 8 which was dependent on quizartinib plasma concentrations in modelling analyses. 6, 7 Previous pharmacokinetic (PK) studies indicate that quizartinib demonstrates dose-proportional increases in exposure, is extensively metabolised, is predominantly eliminated in faeces, has a median effective half-life of 73 hours (data on file, Daiichi Sankyo, Inc),
and accumulates approximately 5-fold (data on file, Daiichi Sankyo, Inc) after continuous once-daily dosing. 9 Quizartinib is primarily metabolised by cytochrome P450 3A (CYP3A), and 1 of the metabolites is the mono-oxidative product AC886, which is biologically active.
AC886 is also the only other major species, besides quizartinib, detected in plasma, 9 with a relative metabolite-to-parent ratio of approximately 0.6 following repeated daily dosing in a phase 2 trial of quizartinib in patients with AML (data on file, Daiichi Sankyo, Inc).
AC886 is also a substrate for CYP3A and can be further metabolised by the enzyme (data on file, Daiichi Sankyo, Inc).
Patients with AML are at high risk for invasive fungal infections, 10, 11 and some antifungal agents, such as azoles, that are used to prevent and treat invasive fungal infections in patients with AML are known to inhibit CYP3A. 11, 12 Because quizartinib is metabolised by CYP3A enzymes, coadministration of such therapies could alter overall exposure to quizartinib. Therefore, understanding the effect of drugs that inhibit CYP3A on the PK of quizartinib and AC886 is important for clinically safe and effective use of quizartinib. This drug-drug interaction study was performed to provide dosing guidance for quizartinib when it is coadministered with strong or moderate CYP3A inhibitors. What this study adds
• The results of this study provide information regarding dose adjustments for quizartinib in combination with CYP3A inhibitors for clinically safe and effective use of quizartinib.
• When administered with a strong CYP3A inhibitor, reducing quizartinib doses from 30 to 20 mg or from 60 to 30 mg is recommended.
• No dose adjustment is needed when quizartinib is coadministered with a moderate or weak CYP3A
inhibitor. The study protocol, amendments and informed consent forms were reviewed and approved by the institutional review board at each site.
All subjects provided written informed consent before any studyrelated procedure took place. A schematic of the study design, including timeline of treatments and sample collection, is shown in Figure 1 .
| Eligibility
Healthy males and females, aged 18-55 years, were eligible for enrolment into the study. Key inclusion criteria were body mass index of 
| Randomisation and treatments
Subjects were randomised at a ratio of 1:1:1 to 1 of 3 treatment arms:
ketoconazole + quizartinib arm, fluconazole + quizartinib arm, or quizartinib arm as shown in Figure 1 . 
| Sample collection and analytic methodology
Blood samples for measurement of plasma quizartinib and AC886 concentrations were collected from all subjects before quizartinib dosing Interference of quizartinib and AC886 (at 500 and 100 ng/mL, respectively) was evaluated, and no interference from these compounds was observed. For ketoconazole at the LLOQ, precision was 8.6 (%CV) and accuracy ranged from 110.2 to 89.8%.
For ketoconazole at 8000 ng/mL, precision was 2.3 (%CV) and accuracy ranged between 103.9 and 96.1%. For fluconazole at the LLOQ, precision was 9.5 (%CV) and accuracy ranged from 107.1 to 93.0%.
For fluconazole at the upper limit of quantitation, precision was 1.9
(%CV) and accuracy ranged between 102.4 and 97.6% between runs.
| Safety
All randomised subjects who received quizartinib or at least 1 dose of CYP3A inhibitor were included in the safety analysis population.
Safety was assessed with physical examinations, vital signs, 12-lead electrocardiograms, AE evaluations, and clinical laboratory tests.
Haematology, chemistry and urinalysis determinations were performed by a local laboratory. AEs were evaluated during the study according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.03 and assessed for severity, relation to study drugs and clinical significance.
| PK analyses
The PK analysis population consisted of all subjects who received the quizartinib dose and had evaluable maximum observed plasma con- together with concentrations around time to C max (T max ) on Day 8, they also allowed for assessment of consistency with published data.
For quizartinib, time points on day 1 (0, 0.25, 0. 
| Statistics
A sample size of 25 subjects per group was determined to yield ≤10% Inc., Cary, NC, USA).
| Simulation analysis
Given the linear PK of quizartinib, predictions of PK parameters, including steady-state C max (C max,ss ), AUC from time 0 to the end of the dosing interval (AUC τ ) and T max at steady-state (T max,ss ), were simulated by superpositioning using Phoenix 6.3 (Certara USA, Inc., Princeton, NJ, USA). Statistical analysis and determination of drugdrug interaction for predicted PK parameters, AUC τ and C max,ss , were performed as described above for exposure parameters (AUC inf , AUC last , C max ).
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHAR-MACOLOGY, 16 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18. 17 3 | RESULTS
| Demographics and baseline characteristics
A total of 93 subjects were enrolled in the study, with 31 randomised into each treatment arm; 89 subjects received quizartinib and 86 subjects completed all study procedures ( Figure 2 ). Overall, 7 subjects discontinued from the study: 4 prior to receiving quizartinib and 3 after receiving quizartinib. Of the subjects who withdrew before receiving quizartinib, 2 withdrew consent, 1 discontinued for AE (bacterial vaginitis) and 1 was withdrawn by the sponsor. Of the 3 subjects who discontinued after receiving quizartinib treatment, 1 discontinued for AE (animal bite) and 2 were lost to follow-up. Demographics and baseline characteristics were generally similar between the treatment groups (Table 1) . (Table S1 ). However, as parent quizartinib is the major component in plasma, total quizartinib + AC886 displayed similar increases in these PK parameters as parent quizartinib, albeit of slightly smaller magnitude, with geometric LS mean C max , AUC last and AUC inf values of 5, 59 and 82%, respectively, with ketoconazole coadministration (Table S2 ). As expected due to the potential interaction with CYP3A4 inhibitors, the 90% CIs for the geometric mean ratios for C max , AUC last and AUC inf for both quizartinib and AC886 were outside the bioequivalence interval of 80-125% (Table 2 and Table S1 ).
| PK results

Mean
The T 1/2 of quizartinib and AC886 increased by 46 and 96%, respectively, when quizartinib was coadministered with ketoconazole.
The CL/F of quizartinib decreased by 50% when ketoconazole was coadministered with quizartinib.
Simulation of steady-state PK predicted significant increases in quizartinib exposure after repeated daily dosing with coadministration (Table 3 ). The C max,ss and AUC τ were predicted to increase by 86% and 96%, respectively. The T max,ss was similar when quizartinib was dosed alone or with ketoconazole (Table 3 ). Exposure to the metabolite AC886 at steady-state was decreased by 14 and 18% for geometric LS means of AUC τ and C max , respectively, with ketoconazole coadministration compared with quizartinib alone (Table S3 ). In addition, the metabolite:parent ratio of concentrations was found to be consistent over 21 days for each of the treatment arms. As expected from the concentration-time profiles, subjects receiving ketoconazole had the lowest ratios of metabolite:parent followed by the group that received fluconazole. The group that received quizartinib alone had the highest ratios.
| Effect of fluconazole on quizartinib PK
The geometric LS means for quizartinib C max , AUC last and AUC inf increased by 11, 20 and 20%, respectively, with fluconazole coadministration. The 90% CI of the geometric LS mean for C max was entirely within the 80-125% prespecified interval, while the upper limits of the 90% CIs for AUC last and AUC inf were 137 and 138%, respectively, falling outside the upper 125% limit (Table 2 ). Mean T 1/2 and CL/F of quizartinib had modest changes of~10 and 17%, respectively, with fluconazole coadministration. The trends in plasma PK parameters of AC886 and quizartinib + AC886 were similar to those observed for parent quizartinib (Tables S1 and S2) .
Consistent with the single-dose results, simulation of steady-state concentration of quizartinib in plasma after repeated daily dosing of quizartinib with fluconazole vs alone resulted in minor changes to AUC τ and C max,ss (data not shown).
| Safety
Overall, coadministration of ketoconazole or fluconazole with quizartinib was well tolerated in healthy subjects.
The proportions of subjects with AEs were similar across groups.
Thirty-six subjects experienced at least 1 AE during the study: 13 (41.9%) subjects in the quizartinib arm, 9 (29.0%) subjects in the quizartinib + ketoconazole arm and 14 (45.2%) subjects in the C max,ss , predicted steady-state peak concentration; AUC τ , area under the plasma concentration-time curve from time 0 to the end of the dosing interval; T max,ss , predicted actual sampling time to reach maximum observed concentration; LS, least square; SE, standard error; CI, confidence interval; CV, coefficient of variation; SD, standard deviation; min, minimum; max, maximum; n, number of subjects used for simulation.
fluconazole + quizartinib arm. Of the 36 subjects who experienced AEs, a large majority of subjects (32 subjects, 88.9%) experienced mild/Grade 1 AEs. Three subjects (8.3%) experienced moderate/Grade 2 AEs and 1 subject (2.8%) experienced a severe/Grade 3 AE. The severe AE was musculoskeletal stiffness of the neck, which was not considered related to any of the study medications, and resolved in 15 days. There were no life-threatening/Grade 4 AEs or deaths. There were no serious AEs observed in the study.
Only 5 (5.4%) subjects overall experienced AEs considered to be possibly related to quizartinib. These 5 subjects were distributed throughout the treatment groups as follows: 3 subjects in the quizartinib arm, 1 in the ketoconazole + quizartinib arm, and 1 in the fluconazole + quizartinib arm. The most common AEs related to quizartinib were gastrointestinal disorders and were experienced by 1 subject in each treatment arm.
No significant abnormalities in vital signs or changes to QTcF (Table S4) , haematology or clinical chemistry were observed during the study.
| DISCUSSION
There is substantial risk for infections, including invasive fungal infections, in patients with AML. 10, 11 As a result, concomitant use of antifungals is common in these patients. Some antifungals (such as azoles) that are used to prevent and treat invasive fungal infections in patients with AML can inhibit CYP3A. 11, 12 As quizartinib is primarily Consistent with in vitro observations that quizartinib is a substrate for CYP3A, increases in quizartinib exposure were observed when quizartinib was coadministered with a strong or moderate CYP3A
inhibitor. In addition, moderate inhibition of CYP3A by fluconazole had no significant effect on the PK of AC886, the main and biologically active metabolite of quizartinib. However, strong inhibition of CYP3A by ketoconazole decreased C max and increased the T 1/2 and T max of AC886. This resulted in relatively flat plasma concentrationtime profiles of AC886 in the presence of ketoconazole, preventing reliable estimation of T 1/2 of AC886 in several subjects (Table S1 ).
These changes are consistent with previous data demonstrating that AC886 is produced when quizartinib is metabolised by CYP3A 9 and is, itself, also a substrate for CYP3A (data on file, Daiichi Sankyo, Inc).
After administration of an oral dose, quizartinib is the major moiety in circulation, and AC886 is a smaller component. The observed increase in exposure to the total circulating active moiety (quizartinib + AC886) because of CYP3A inhibition was similar in trend and magnitude to the increased exposure for quizartinib alone. There was an approximate 2-fold increase in quizartinib AUC when quizartinib was coadministered with a strong CYP3A inhibitor, ketoconazole. Despite increases in quizartinib exposure when administered with CYP3A
inhibitors, there were no differences observed in AEs possibly related to quizartinib following a single dose in healthy subjects across the 3 treatment arms.
As a result of the long half-life of quizartinib, the drug exhibits an This drug interaction study was conducted in healthy subjects, while quizartinib is used to treat patients with AML. There are reports that intestinal mucositis and neutropenia, experienced by AML patients, may impact oral absorption of posaconazole 18 or clearance of vancomycin, 19 respectively. An exploratory exposure-response analysis for febrile neutropenia, a common AE in AML patients, was performed in the phase 2 study. No clear correlation between PK parameters and the frequency of febrile neutropenia was apparent.
In a population PK analysis for AML patients who received quizartinib with or without strong CYP3A inhibitors, a similar degree of increase in quizartinib exposure was estimated to that observed in this study (data on file, Daiichi Sankyo, Inc). Furthermore, the dose reduction for strong CYP3A inhibitors based on this study was implemented in a recently completed phase 3 study (QuANTUM-R), which showed a positive study outcome. 20 The results of this study suggest reducing the dose of quizartinib when administered concomitantly with strong CYP3A inhibitors that are medically necessary for the care of the patient. Modeling of the concentration/QT relationship in a prior phase 2 study indicated that quizartinib prolongs QT intervals in a concentration-dependent manner. 7 A robust exposure-response model for concentration-QTc (C- previous clinical studies in patients with AML. [5] [6] [7] 21 The increased exposure to quizartinib with ketoconazole supports reducing quizartinib doses in patients receiving a strong CYP3A inhibitor. Based on the fluconazole arm data, no dose reduction is needed when quizartinib is coadministered with a moderate or weak CYP3A inhibitor. This approach to dose adjustment aims to minimise variability in drug exposure and reduce the risk of QT prolongation in patients receiving quizartinib in conjunction with a drug that inhibits its metabolism via CYP3A. In the QuANTUM-R phase 3 study that evaluated patients with relapsed/refractory FLT3-ITD-mutated AML, the quizartinib dosage regimen was a 30-mg starting dose followed by escalation to 60 mg; the study showed prolonged overall survival vs standard chemotherapy. 20 In the ongoing QuANTUM-First phase 3 study evaluating patients with newly diagnosed FLT3-ITD-mutated AML, the quizartinib group is receiving a 40-mg dose in combination with standard induction and consolidation chemotherapy, then a 30-mg starting dose followed by 60 mg as the target dose. 22 The findings of the current study support dosage reductions in patients receiving a strong CYP3A inhibitor. In scenarios wherein patients would normally receive 30 mg (or 40 mg; administered as quizartinib dihydrochloride, equivalent to 26.5 or 35.3 mg, respectively, in free-base form) or 60 mg of quizartinib (administered as quizartinib dihydrochloride, equivalent to 53 mg in free-base form), doses of quizartinib should be reduced to 20 or 30 mg, respectively (administered as quizartinib dihydrochloride, equivalent to 17.7 or 26.5 mg, respectively, in freebase form), in patients receiving a strong CYP3A inhibitor. 23 This guidance was implemented in the 2 phase 3 trials, and additional population PK analysis from QuANTUM-R will further define the effects of dose modification on quizartinib PK when administered with strong CYP3A inhibitors.
